Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 139Esophageal Neoplasms 125Pancreatic Neoplasms 96Esophageal Squamous Cell Carcinoma 84Colorectal Neoplasms 66Adenocarcinoma Of Esophagus 53Stomach Neoplasms 40Carcinoma, Hepatocellular 40Colonic Neoplasms 19Anus Neoplasms 18Neoplasms 14Liver Neoplasms 12Cholangiocarcinoma 10Adenocarcinoma 8Carcinoma, Squamous Cell 7Bile Duct Neoplasms 7Anal Canal Carcinoma 7Head and Neck Neoplasms 6Breast Neoplasms 6Brain Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Lung Neoplasms 5Gastrointestinal Neoplasms 5Gallbladder Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Sarcoma 4Vulvar Neoplasms 3

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Esophagogastric Cancer × Radiotherapy × Gastrointestinal × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡